Is a 2 mg semaglutide dose right for weight loss?

The misconception worth correcting: why '2 mg semaglutide' keeps appearing

The confusion is understandable. Semaglutide comes in several licensed medicines (Ozempic for type 2 diabetes, Rybelsus tablets also for diabetes, and Wegovy for weight management) and each uses a different dose range. Ozempic's top strength is 2 mg. That figure circulates widely, and people researching weight loss sometimes land on it and assume it applies to Wegovy too. It doesn't.

For weight management, the product is Wegovy, and its highest injection dose at standard approval is 2.4 mg, not 2 mg. Ozempic is not licensed for weight loss in the UK, and prescribing it for that purpose would be off-label. The NHS semaglutide medicines page sets out the distinction clearly. If you have been quoted or sold a "2 mg weight-loss dose", that warrants a closer look at the source.

Letting go of that figure also matters practically. Because the actual schedule tops out at 2.4 mg (with a higher 7.2 mg option now approved) someone expecting a 2 mg step will find it simply isn't there. You move from 1.7 mg straight to 2.4 mg, then potentially to 7.2 mg if your prescriber considers it appropriate and you meet the eligibility criteria for that pen.

What the actual Wegovy dose steps do, and why the sequence exists

Each step in the Wegovy injection schedule serves a purpose. The 0.25 mg starting dose is there to settle your system, it produces little weight-loss effect on its own, but it lets your body adjust to the medicine before the therapeutic doses come into play. Nausea is the most commonly reported early side effect, and the slow climb is specifically designed to reduce it.

From there, most patients move through 0.5 mg, 1.0 mg, a step where semaglutide begins to deliver more noticeable weight-loss effects for many people, and 1.7 mg before reaching 2.4 mg, which was the standard maintenance dose when Wegovy launched. Clinical trial data at 2.4 mg showed an average weight reduction of around 15% over 68 weeks, published in the STEP 1 trial in the New England Journal of Medicine. That is a meaningful result, but it does assume patients reach and stay on the maintenance dose.

Not everyone does. Some people find 1.7 mg is the highest dose they tolerate comfortably, and that is a clinical judgement made with their prescriber rather than a failure. Dose decisions are shaped by how well you are tolerating side effects, your weight response at each step, and any other health factors in the picture. A prescriber reviews all of that; the dose ladder is a starting framework, not a rigid instruction.

You can read more about how the semaglutide dose schedule works overall if you want to understand the full picture beyond any single step.

The 7.2 mg pen and what it changes for patients already on 2.4 mg

On 14 April 2026, the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, one pre-set weekly injection, built-in covered needle, locks after use. This approval applies to adults with a BMI of 30 or above only; it is not available for lower BMIs or for the separate cardiovascular indication.

Trial data for 7.2 mg reported average weight loss of around 20.7% over 72 weeks, which narrows the gap considerably with the highest tirzepatide (Mounjaro) results. For context, the Wegovy highest-dose page covers the evidence and eligibility for this option in more detail.

Starting dose remains 0.25 mg even for patients aiming for 7.2 mg; the titration steps are the same. Patients already established on 2.4 mg weekly do not jump straight to 7.2 mg, the step is made by the prescriber when clinically appropriate. Whether a specific pen format is available is confirmed at consultation; availability of individual dose formats can vary. If you want to understand what the intermediate titration involves before reaching that point, you can read about semaglutide at the 7 mg stage and what patients typically experience during that part of the journey.

None of this changes the fact that there is no 2 mg rung in the schedule. The jump is from 1.7 mg to 2.4 mg, full stop.

What this means if you are considering Wegovy privately

Wegovy is a prescription-only medicine. In the UK, that means a prescriber has to assess you before any dose is supplied or changed, including moves between steps. If you are reading about dose options to decide whether to start, the most useful next step is a consultation with a qualified prescriber who can look at your full picture.

For a sense of what private treatment involves financially, the weight-loss treatments page sets out how treatment is structured and what is included in the price. Private treatment through a regulated online pharmacy means no waiting list, but it does require the same clinical assessment as any other route. A named prescriber reads your answers (not software) on the same day you submit.

Common side effects across all dose steps are mainly gastrointestinal: nausea, loose stools, constipation, and reflux are reported most often, and they tend to settle after the first couple of weeks at a new dose. Severe or persistent stomach pain that spreads to the back should always be assessed urgently by a clinician. If you want to compare Wegovy with other weight-loss injection options, the Wegovy overview is a good starting point, and the 2.4 mg Wegovy page covers the standard maintenance dose in detail.

If the injection format is not for you, the weight-loss treatments overview covers oral options too, including the Wegovy tablet approved by the MHRA in June 2026. Our clinical team can help work out which option fits your situation when you start your free consultation.